KRAS and non-small cell lung carcinoma: Recent advances in the understanding of the structure of mutant KRAS have led to the development of new allele-specific inhibitors that have shown promising efficacy in pretreated advanced KRAS mt G12C NSCLC patients in phase I/II clinical trials.